LINC01133 and LINC01243 are positively correlated with endometrial carcinoma pathogenesis
- PDF / 1,679,778 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 6 Downloads / 206 Views
GYNECOLOGIC ONCOLOGY
LINC01133 and LINC01243 are positively correlated with endometrial carcinoma pathogenesis Weina Yang1 · Yingying Yue1 · Fei Yin2 · Zhiying Qi1 · Ruimeng Guo1 · Yanying Xu1 Received: 30 December 2019 / Accepted: 5 September 2020 © Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract Purpose To characterize the role of two long non-coding RNAs (lncRNAs), LINC01133 and LINC01243, in endometrial carcinoma (EC) pathogenesis. LINC01133 is an lncRNA that has been implicated in many cancers, and LINC01243 is a newly identified lncRNA identified from the NCBI GEO database. Methods We studied the effect of LINC01133 and LINC01243 on EC malignancy using siRNA knockdown and real-time quantitative polymerase chain reaction (RT-qPCR), flow cytometry, Annexin V-FITC/propidium iodide double staining, Transwell, and scratch invasion assays in two EC cell lines (Ishikawa and HEC-1-A cells). Results We first confirmed the partial knockdown of both LINC01133 and LINC01243 expression in Ishikawa and HEC1-A cells using RT-qPCR. Following confirmation of lncRNA knockdown, we assessed the effect of knockdown on EC malignancy. We observed reduced EC cell proliferation using the CCK-8 assay, as well as cell cycle arrest and increased apoptosis in both EC cell lines. Furthermore, Transwell and scratch invasion assays revealed decreased migration and invasion of the two EC cell lines, respectively. Conclusion We demonstrated that LINC01133 and LINC01243 expression are associated with EC development and progression. Our findings suggest a potential role for these lncRNAs as novel EC biomarkers. Keywords lncRNA · Endometrial carcinoma · Cell cycle · Apoptosis · Migration · Invasion · Biological function
Introduction Endometrial carcinoma (EC) is the most common gynecological cancer that primarily affects postmenopausal women and is typically characterized by vaginal bleeding. This cancer has been associated with increased morbidity and mortality [1]. The incidence rate of EC has been rising in 26 out of 43 countries according to a study on the international trends in EC occurrence between 1978 and 2013 [2]. EC accounts for 4.8% of all malignant tumors in women Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00404-020-05791-0) contains supplementary material, which is available to authorized users. * Yanying Xu [email protected] 1
Department of Gynecology, The Second Hospital of Tianjin Medical University, Tianjin, China
Tianjin University of Traditional Chinese Medicine, Tianjin, China
2
and 2.1% of all cancer-related deaths [3]. Hysterectomy is currently the primary treatment strategy for EC. Patients with advanced stage EC (stage III or IV) or aggressive EC subtypes showed poorer disease prognosis and lower survival rate compared to those with early stage EC (stage I) [4]. Of the two EC subtypes, estrogen-sensitive Type I EC is more prevalent but less aggressive than Type II EC [4–6]. Changes in the expression levels of oncogenes, tumor sup
Data Loading...
